Roche's Strategic Push into Obesity Drug Market
Swiss drugmaker Roche is advancing its experimental obesity drug CT-388 into a late-stage trial, aiming to compete with industry leaders Eli Lilly and Novo Nordisk. The company aims to capture significant market share, estimating the obesity drug market could reach $150 billion annually by the early 2030s.
Swiss pharmaceutical giant Roche has set its sights on making a big splash in the burgeoning weight-loss market, aligning itself with leaders Eli Lilly and Novo Nordisk. The company has taken a significant step by moving its experimental obesity drug, CT-388, into a phase III trial.
This move highlights Roche's strategy to compete with the dominant players in the lucrative sector, which analysts predict could reach a $150 billion valuation annually by the early 2030s. The drug, acquired through Roche's purchase of U.S. biotech firm Carmot Therapeutics, is considered a key element in their ambitious plan.
Roche executives have expressed confidence in their ability to capture market share, eyeing becoming a top-three player in the obesity drug space. They plan to launch six drug candidates by 2030, potentially turning three into billion-dollar blockbusters.
(With inputs from agencies.)
Google News